Journals / Çocuk ve Gençlik Ruh Sağlığı Dergisi / 2014 / Cilt: 21 - Sayı: 2

THE CLINICAL AND DEMOGRAPHIC FEATURES OF CASES WITH PERVASIVE DEVELOPMENTAL DISORDER EVALUATED IN A TRAINING AND RESEARCH HOSPITAL

BİR EĞİTİM VE ARAŞTIRMA HASTANESİNDE DEĞERLENDİRİLEN YAYGIN GELİŞİMSEL BOZUKLUK OLGULARININ KLİNİK VE DEMOGRAFİK ÖZELLİKLERİ

Pages
95–104
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was found that 27.9% of the cases (n=83) had been using at least one and/or more medication with the most commonly recommended drug being risperidone by 61.4% (n=51) and that the presence of a psychiatric comorbidity was a predictor of psychotropic medication use (p=0.017).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to assess cases diagnosed with any disorder that would be included within the broad title pervasive developmental disorders (PDD) according to DSM-IV-TR classifi cation, to determine the cases’ clinical and sociodemographic features and to compare the subtypes.
📊
Key Findings & Data:Method: The medical records of the cases that had applied to our unit between the dates May 15, 2012 and May 15, 2013 were screened.
💡
Conclusion & Impact:It was found that 27.9% of the cases (n=83) had been using at least one and/or more medication with the most commonly recommended drug being risperidone by 61.4% (n=51) and that the presence of a psychiatric comorbidity was a predictor of psychotropic medication use (p=0.017).
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: This study aimed to assess cases diagnosed with any disorder that would be included within the broad title pervasive developmental disorders (PDD) according to DSM-IV-TR classifi cation, to determine the cases’ clinical and sociodemographic features and to compare the subtypes. Method: The medical records of the cases that had applied to our unit between the dates May 15, 2012 and May 15, 2013 were screened. Demographic and clinical features of cases with PDD were assessed and SPSS 17.0 program was used for statistical analysis. Results: Out of a total 25,013 applicants, 298 (1.2%) met the criteria for PDD spectrum. Mean age of the cases was 8.7±3.9 years; 79.5% were boys (n=237) and 77.2% were a resident in Ankara province at the time of the study. Sixty- three percent of the cases (n=188) were diagnosed with autistic disorder while 31.2% (n=93), 5% (n=15), and 0.7% (n=2) were diagnosed with PDD-not otherwise specifi ed (PDD-NOS), Rett Syndrome, and Asperger Syndrome, respectively. At least one comorbid psychiatric disorder was found in 50.3% of the sample (n=150). For girls, presence of comorbid severe mental retardation (11.5%, n=11) and epilepsy (14.8%, n=9) were found to be signifi cantly more frequent then boys (p=0.018, p=0.008, respectively). It was found that 27.9% of the cases (n=83) had been using at least one and/or more medication with the most commonly recommended drug being risperidone by 61.4% (n=51) and that the presence of a psychiatric comorbidity was a predictor of psychotropic medication use (p=0.017). Discussion: The most frequently encountered disorder within PDD was autism and the fi nding regarding epilepsy comorbidity in the clinical picture for female gender was noticed. The presence of any other comorbid psychiatric disorder that was observed for approximately every other case was a predictor of psychotropic medication use at the same time.

Özet

Amaç: Bu çalışmada DSM-IV-TR’ye göre “Yaygın Gelişimsel Bozukluklar (YGB)” başlığı altında yer alan bozukluklardan herhangi biri ile tanılanan olguların incelenmesi, klinik ve sosyodemografi k özelliklerinin saptanması ve alt tiplere göre karşılaştırılması hedefl enmiştir. Yöntem: Kliniğimize 15 Mayıs 2012-15 Mayıs 2013 tarihleri arasında başvuran olguların kayıtları taranarak, YGB olgularının demografi k ve klinik özellikleri değerlendirilmiş, istatistiksel analiz için SPSS 17.0 programı kullanılmıştır. Sonuçlar: Toplam 25.013 başvurudan 298’inin (%1,2) YGB spektrumunda olduğu saptanmıştır. Olguların yaş ortalamasının 8,7±3,9 yaş, %79,5’inin (n=237) erkek cinsiyette olduğu ve %77,2’sinin Ankara ilinde yaşadığı bulunmuştur. Olguların %63’üne (n=188) otizm, %31,2’sinin (n=93) Başka Türlü Adlandırılamayan (BTA)-YGB, %5’inin (n=15) Rett Sendromu ve %0,7’sinin (n=2) Asperger Sendromu tanısı konulduğu belirlenmiştir. Örneklemin %50,3’ünde (n=150) tabloya eşlik eden en az bir psikiyatrik bozukluk saptanmıştır. Kız çocuklarında ağır mental retardasyon (%11,5, n=11) ve epilepsi (%14,8, n=9) varlığı istatistiksel olarak anlamlı düzeyde erkeklerden daha fazla bulunmuştur (p=0,018, p=0,008 sırasıyla). Olguların %27,9’una (n=83) en az bir ve/ veya daha fazla ilaç tedavisi uygulandığı, en sık olarak %61.4 (n=51) ile risperidon önerildiği, psikiyatrik komorbidite varlığının ilaç tedavisini öngördüğü belirlenmiştir (p=0,017). Tartışma: YGB spektrumunda en sık görülen bozukluk otizm olup kız cinsiyetinde epilepsinin tabloya eşlik etmesi dikkati çekmiştir. Yaklaşık her iki olgudan birinde eşlik eden bir başka psikiyatrik bozukluk varlığı aynı zamanda ilaç tedavisini de öngörmektedir.

🔖

Cite This Article

GÖKER, Z., GÜNEY, E., DİNÇ, G., HEKİM, Ö., ÜNERİ, Ö. (2014). THE CLINICAL AND DEMOGRAPHIC FEATURES OF CASES WITH PERVASIVE DEVELOPMENTAL DISORDER EVALUATED IN A TRAINING AND RESEARCH HOSPITAL. Çocuk ve Gençlik Ruh Sağlığı Dergisi, Cilt: 21 - Sayı: 2, 95–104. https://ajindex.com/articles/154640

References (12)

  1. Amerikan Psikiyatri Birliği, Ruhsal Bozuklukların Tanısal ve İstatistiksel Elkitabı, Gözden Geçirilmiş Dördüncü Basım: DSM-IV-TR (2007). Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention (2012) Prevalence of autism spectrum disorders-Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 61:1-19.
  2. Baird G, Simonoff E, Pickles A ve ark. (2006) Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 368: 210-215.
  3. Brereton AV, Tonge BJ, Einfeld SL (2006) Psychopathology in children and adolescents with autism compared to young people with intellectual disability. J Autism Dev Disorder 36:863-870.
  4. Christensen D, Van Naarden Braun K, Doernberg NS ve ark. (2014) Prevalence of cerebral palsy, co-occurring autism spectrum disorders, and motor functioning-Autism and Developmental Disabilities Monitoring Network, USA, 2008. Dev Med Child Neurol 56:59-65.
  5. Coury DL, Anagnostou E, Manning-Courtney P ve ark. (2012) Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics 130 suppl 2: S69-76. Fombonne E (2009) Epidemiology of pervasive developmental disorders. Pediatr Res 65:591-8.
  6. Francis A, Msall M, Obringer E, Kelley K (2013) Children with autism spectrum disorder and epilepsy. Pediatr Ann 42: 255-260
  7. Giarelli E, Wiggins LD, Rice CE ve ark. (2010) Sex differences in the evaluation and diagnosis of autism spectrum disorders among children. Disabil Health J 3: 107-116.
  8. Hanson E, Cerban BM, Slater CM, Caccamo LM, Bacic J, Chan E (2003) Brief report: Prevalence of attention defi cit/ hyperactivity disorder among individuals with an autism spectrum disorder. J Autism Dev Disord 43: 1459-1464.
  9. Hedvall A, Westerlund J, Fernell E, Holm A, Gillberg C, Billstedt E (2014) Autism and developmental profi les in preschoolers: stability and change over time. Acta Paediatr 103:174-181.
  10. Kent JM, Kushner S, Ning X ve ark. (2013) Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. J Autism Dev Disord 43: 1773-1783.
  11. Levy SE, Mandell DS, Schultz RT (2009). Autism. Lancet 374:1627-38.
  12. Marcus RN, Owen R, Manos G, ve ark. (2011) Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-l